Grifols Stock (NASDAQ:GRFS), Trade Ideas

Grifols

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

News

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

FAAS

FAST

GRFS

LOVE

NBTX

NYXH

RCEL

U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday.

CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Penny Stocks

Intraday Update

ABTS

ALAB

AMTX

ANNX

ATER

BACK

BCAN

BIOL

BNAI

BTDR

CUTR

CZOO

DNTH

EGOX

FRSX

GRDI

GTBP

ISPR

JOAN

LAAC

LICY

LULU

LXEH

MRNO

NKTX

NVFY

OCGN

OTLK

RETO

SINT

SLNA

SMLP

TROO

YTEN

Shares of  Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

BGNE

BROS

SOUN

U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday.

Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Grifols, S.A. - American Depositary Shares

Grifols SA

<a href="https://www.grifols.com/en/view-news/-/news/grifols-achieves-positive-results-from-phase-4-study-of-fanhdi-double-inactivated-human-anti-hemophilic-factor-in-patients-with-von-willebrand-disease">https://www.grifols.com/en/view-news/-/news/grifols-achieves-positive-results-from-phase-4-study-of-fanhdi-double-inactivated-human-anti-hemophilic-factor-in-patients-with-von-willebrand-disease</a>
&nbsp;

Biotech

General

Grifols Achieves Results From Phase 4 Study Of Fanhdi In Patients With Von Willebrand Disease

U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday.
Shares of CarMax, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kmx#NYSE">KMX</a>) fell sharply in today&rsquo;s pre-market trading after the company reported lower-than-expected <a href="https://www.benzinga.com/quote/KMX/earnings">fourth-quarter earnings</a>.
<ul>
<li>CarMax posted quarterly earnings of 32 cents per share, missing market estimates of 49 cents per share. The company&rsquo;s quarterly sales came in at $5.63 billion versus expectations of $5.79 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.</li>
<li>CarMax shares dipped 9.1% to $72.06 in pre-market trading.</li>
<li>Here are some big stocks recording losses in today&rsquo;s pre-market trading session.</li>
<li>The Lovesac Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/love#NASDAQ">LOVE</a>) shares fell 13% to $20.30 in pre-market trading after the company reported worse-than-expected fourth-quarter results and issued first-quarter guidance.</li>
<li>Nyxoah S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nyxh#NASDAQ">NYXH</a>) shares dipped 12.4% to $9.30 in pre-market trading.</li>
<li>AVITA Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcel#NASDAQ">RCEL</a>) shares fell 11.6% to $12.76 in pre-market trading after the company announced an update to its expected commercial revenue for the first quarter of 2024. BTIG downgraded the stock from Buy to Neutral.</li>
<li>DigiAsia Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faas#NASDAQ">FAAS</a>) shares fell 7.1% to $8.11 in pre-market trading after jumping around 19% on Wednesday.</li>
<li>Nanobiotix S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbtx#NASDAQ">NBTX</a>) shares declined 6.2% to $6.00 in pre-market trading after gaining over 6% on Wednesday.</li>
<li>Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) shares fell 5% to $6.62 in pre-market trading.</li>
<li>Fastenal Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fast#NASDAQ">FAST</a>) shares declined 5.1% to $70.90 in pre-market trading following worse-than-expected first-quarter financial results.</li>
<li>Mercury General Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mcy#NYSE">MCY</a>) fell 4.5% to $49.00 in pre-market trading. Mercury General is expected to report first-quarter earnings after the markets close on Tuesday, April 30, 2024.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38176505/jim-cramer-says-wesco-international-is-a-buy-recommends-buying-this-stock-under-20"> Jim Cramer Says WESCO International Is A Buy, Recommends Buying This Stock Under $20</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Grifols Says Regarding Adjustments For Cost Savings, Operational Improvements, And Synergies Made To Consolidated EBITDA Under Credit Agreement, Confirms That This Is Not Used As An Alternative Measure Of Performance

<ul>
<li>Grifols&#39; in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections</li>
</ul>
<ul>
<li>Arboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalent</li>
</ul>
<ul>
<li>CE mark for Grifols&#39; Procleix ArboPlex Assay reinforces the company&#39;s leadership in transfusion medicine and commitment to ensuring the safety of the world&#39;s blood supply</li>
</ul>

Grifols Achieves Milestone In Transfusion Medicine With CE Mark For Procleix ArboPlex Assay

Shares of Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) fell sharply during Friday&rsquo;s session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/CUTR/earnings">fourth quarter adjusted EPS results</a>.
Cutera posted adjusted loss of $1.36 per share, compared to market estimates for a loss of 94 cents per share. The company&rsquo;s quarterly sales came in at $49.540 million, versus expectations of $47.500 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Cutera shares dipped 26.5% to $1.6899 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Murano Global Investments PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) shares jumped 147.5% to $23.94 after falling 46% on Thursday.</li>
<li>Nova LifeStyle, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvfy#NASDAQ">NVFY</a>) surged 120% to $4.0301 after gaining around 22% on Thursday.</li>
<li>BIOLASE, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biol#NASDAQ">BIOL</a>) shares climbed 50.4% to $0.2256 after the company reported better-than-expected fourth-quarter earnings results.</li>
<li>IMAC Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/back#NASDAQ">BACK</a>) gained 41.1% to $1.8204.</li>
<li>Summit Midstream Partners, LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smlp#NYSE">SMLP</a>) surged 36.1% to $26.45 after the company announced the sale of its Utica position for $625 million.</li>
<li>Outlook Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otlk#NASDAQ">OTLK</a>) gained 32.1% to $9.30 after the company announced it received a positive European Union CHMP opinion for ONS-5010 as a treatment for Wet AMD.</li>
<li>GT Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtbp#NASDAQ">GTBP</a>) gained 27.6% to $4.86.</li>
<li>Aemetis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amtx#NASDAQ">AMTX</a>) rose 21% to $6.21. Aemetis recently announced approval by the U.S. Citizenship and Immigration Services for a $200 million of EB-5 program investment for the Riverbank sustainable aviation fuel, production plant, the dairy renewable natural gas project, the carbon sequestration project and energy efficiency upgrades to the Keyes ethanol plant.</li>
<li>Foresight Autonomous Holdings Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frsx#NASDAQ">FRSX</a>) gained 20.4% to $1.1796. Foresight Autonomous said Eye-Net and Softbank completed technology validation phase for connected mobility applications in Japan.</li>
<li>Intellicheck, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idn#NASDAQ">IDN</a>) gained 19.4% to $2.09 after the company reported a year-over-year increase in fourth-quarter EPS results.</li>
<li>Worthington Steel, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ws#NYSE">WS</a>) climbed 18.8% to $37.92 as the company posted stronger-than-expected results for its third quarter on Thursday.</li>
<li>Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) rose 18.6% to $5.41.</li>
<li>Annexon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/annx#NASDAQ">ANNX</a>) climbed 17.3% to $7.14.</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) gained 12.5% to $1.5090 after gaining 8% on Thursday. Ocugen recently appointed Huma Qamar, MD, MPH as Chief Medical Officer.</li>
<li>Lithium Americas (Argentina) Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/laac#NYSE">LAAC</a>) rose 12.2% to $5.77.</li>
<li>Dianthus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnth#NASDAQ">DNTH</a>) surged 11% to $30.84 following upbeat results.</li>
<li>Griid Infrastructure Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grdi#NASDAQ">GRDI</a>) gained 10.9% to $1.22.</li>
<li>Astera Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alab#NASDAQ">ALAB</a>) rose 9.6% to $70.30.</li>
<li>FedEx Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fdx#NYSE">FDX</a>) rose gained 7.9% to $285.78 after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion share repurchase program.</li>
<li>Foot Locker, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fl#NYSE">FL</a>) rose 5% to $24.85. Citigroup analyst Paul Lejuez upgraded Foot Locker from Sell to Neutral and announced a $24 price target.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) shares fell 36.4% to $2.32. BYND Cannasoft said that the previously announced 1-for-190 reverse stock split of its outstanding shares of common stock has been made effective today, March 22, 2024.</li>
<li>Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) fell 30.4% to $0.0946 after the company announced a proposed public offering of common stock.</li>
<li>Ispire Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) fell 28% to $5.84 after the company announced the pricing of its public offering of 2.05 million shares of common stock at $6.00 per share.</li>
<li>Brand Engagement Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bnai#NASDAQ">BNAI</a>) declined 27.2% to $8.00.</li>
<li>Nkarta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktx#NASDAQ">NKTX</a>) fell 22.2% to $10.10 after the company reported fourth-quarter financial results. Following earnings, Raymond James downgraded the stock from Strong Buy to Outperform.</li>
<li>Yield10 Bioscience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yten#NASDAQ">YTEN</a>) fell 22.7% to $0.3358. Yield10 Bioscience recently announced that the USDA-APHIS Biotechnology Regulatory Services determined that the Camelina sativa varieties may be planted and bred in the United States.</li>
<li>ReTo Eco-Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reto#NASDAQ">RETO</a>) declined 20% to $1.50.</li>
<li>Aterian, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ater#NASDAQ">ATER</a>) fell 18.3% to $2.66.</li>
<li>Lixiang Education Holding Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxeh#NASDAQ">LXEH</a>) dipped 18% to $0.6026.</li>
<li>Lululemon Athletica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>) tumbled 16.6% to $399.36. Lululemon posted better-than-expected results for its fourth quarter, but issued a weak forecast for the first quarter.</li>
<li>TROOPS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/troo#NASDAQ">TROO</a>) declined 16.3% to $1.3798.</li>
<li>Li-Cycle Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/licy#NYSE">LICY</a>) dipped 14% to $1.1096.</li>
<li>Cazoo Group Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NYSE">CZOO</a>) fell 13.8% to $4.0480.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) fell 12.9% to $0.2439 after jumping around 30% on Thursday.</li>
<li>Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) fell 11.3% to $6.01.</li>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) dipped 9.9% to $0.6991 after declining over 6% on Thursday.</li>
<li>Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) fell 9.8% to $7.17.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kc#NASDAQ">KC</a>) fell 9.2% to $3.2950.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares fell 9% to $0.0458 after dipping 16% on Thursday.</li>
<li>NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) shares tumbled 8.1% to $92.63. Nike reported upbeat earnings and sales results for its third quarter on Thursday.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) shares fell 7.8% to $0.1420 after surging 14% on Thursday.</li>
<li>AAR Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/air#NYSE">AIR</a>) fell 5.9% to $60.14 following downbeat sales.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37891280/bitcoin-falls-below-65-000-ondo-solana-among-top-losers"> Bitcoin Falls Below $65,000; Ondo, Solana Among Top Losers </a>

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session

WIIM

Grifols shares are trading lower as investors digest the CNMV's review of the company's financial reports which found "deficiencies" but no significant errors.

<h3>Gainers</h3>
<ul>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) shares moved upwards by 61.5% to $0.24 during Friday's pre-market session. The market value of their outstanding shares is at $4.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) shares moved upwards by 46.73% to $10.33. The market value of their outstanding shares is at $222.9 million. </li>
<li>Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) shares rose 15.46% to $4.18. The market value of their outstanding shares is at $107.3 million. </li>
<li>Monogram Orthopaedics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) stock moved upwards by 13.15% to $2.58. The market value of their outstanding shares is at $81.6 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares increased by 11.49% to $0.29. The company's market cap stands at $7.9 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares moved upwards by 10.16% to $2.71. The company's market cap stands at $22.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares declined by 34.0% to $0.09 during Friday's pre-market session. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares fell 10.87% to $2.05. The company's market cap stands at $40.9 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock decreased by 9.82% to $0.42. The market value of their outstanding shares is at $12.5 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) stock declined by 9.65% to $6.13. The market value of their outstanding shares is at $4.1 billion. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock fell 9.37% to $0.39. The market value of their outstanding shares is at $4.7 million. </li>
<li>Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) shares decreased by 9.1% to $11.8. The company's market cap stands at $579.0 million. The company's, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ETON

MGRM

NTRB

OTRK

TBIO

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday.
Shares of Lululemon Athletica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>) fell sharply in today&rsquo;s pre-market trading after <a href="https://www.benzinga.com/news/earnings/24/03/37881188/lululemon-q4-earnings-revenue-beat-eps-beat-shares-slide-on-weak-q1-guidance">releasing fourth-quarter results.</a>
Lululemon posted better-than-expected results for its fourth quarter, but issued a weak forecast for the first quarter. The company said it sees first-quarter revenue in the range of $2.175 billion to $2.2 billion versus estimates of $2.25 billion. The company anticipates first-quarter earnings of $2.35 to $2.40 per share versus estimates of $2.55 per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Lululemon Athletica shares dipped 12.8% to $417.25 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Ispire Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) shares dipped 11.3% to $7.20 pre-market trading after dipping 15% on Thursday.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) shares fell 10.8% to $2.05 in pre-market trading after jumping 20% on Thursday.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) shares dipped 9.9% to $6.02 in pre-market trading after tumbling over 15% on Thursday.</li>
<li>Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) shares fell 8.6% to $6.20 in pre-market trading after gaining around 8% on Thursday.</li>
<li>NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) shares fell 6.3% to $94.49. Nike reported upbeat earnings and sales results for its third quarter on Thursday.</li>
<li>Dutch Bros Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bros#NYSE">BROS</a>) shares declined 5.9% to $33.52 in pre-market trading. Dutch Bros priced secondary public offering of 8 million Class A common stock at $34 per share.</li>
<li>BeiGene, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bgne#NASDAQ">BGNE</a>) shares declined 5.3% to $155.02 in pre-market trading.</li>
<li>Lufax Holding Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lu#NYSE">LU</a>) shares fell 5.1% to $4.66 in pre-market trading after jumping over 45% on Thursday. The company reported fourth-quarter financial results on Thursday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37885621/investor-optimism-improves-slightly-dow-jumps-over-250-points"> Investor Optimism Improves Slightly; Dow Jumps Over 250 Points </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Spanish Stock Market Supervisor CNMV Says There Were Also Deficiencies In The Presentation Of Alternative Performance Measures, In Particular EBITDA And Debt/EBITDA Ratio; CNMV Sees No Need For Grifols To Restate Accounts; Says At Present, It's Not Possible To Prejudge Potential Consequences Of Any Sanctions For Grifols

Spanish Stock Market Supervisor CNMV Says However, We Have Found Deficiencies In Detail, Accuracy Of Breakdowns, Explanatory Notes In Some Years Of The Period Analyzed

Spanish Stock Market Supervisor CNMV Says Investigations Not Identified Significant Errors In Quantitative Magnitudes Of Grifols' Main Financial Statements For The Period Analyzed; Have Not Found Evidence That The Financial Debt Reported By Grifols Does Not Correspond To Reality

Grifols SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares were down more than 9.1% on Thursday after credit rating agencies Fitch and S&amp;P slashed their ratings for the troubled pharmaceutical company. 
What Happened: Grifols shares are among the worst performers in Spain&#8217;s blue-chip index. 
Fitch cited &#8220;slower-than-expected deleveraging&#8221; as the reason for the downgrade, emphasizing the significant shortfall in free cash flow generation for 2023 and 2024, Reuters noted.&nbsp;
However, there&#8217;s a glimmer of hope as the pending sale of Grifols&#8217; 20% stake in Shanghai RAAS, slated to close in the first half of 2024 pending regulatory approval, could ease the refinancing pressure, according to Fitch.&nbsp;
Meanwhile, S&amp;P echoed similar concerns about Grifols&#8217; cash flow and refinancing risks, leading to its downgrade.
In response to the rating actions, citing Grifols, Reuters highlighted that the company acknowledged the challenges posed by upcoming maturities in 2025 but reassured stakeholders of its commitment to address them promptly.&nbsp;
The Barcelona, Spain-based company emphasized ongoing efforts to enhance leverage levels while maintaining business continuity. 
Grifols recently announced an ambitious operating cash flow generation target for 2024, aiming to surpass €900 million before one-off items. 
The company has set its sights on generating between €2 billion and €2.5 billion in free cash flow before dividends from 2025 to 2027, seeking to reverse the negative trend observed in 2023.
Last week, Gotham City Research&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37517028/spanish-healthcare-firm-grifols-hit-with-new-gotham-citys-short-report-faces-questions-regarding-" rel="noreferrer noopener">issued a new publication</a>&nbsp;about Grifols, questioning the company&#8217;s &#8220;transparency, integrity and ethical conduct.&#8221;
Gotham said Grifols&#8217; representation of the lending activity was &#8220;neither detailed nor correctly identifies the nature of the transactions.&#8221;
As per the initial Gotham report released in January, &#8216;Grifols&#8217; actual debt could be closer to €8.9 billion, significantly higher than the reported €8 billion. They estimate that the company&#8217;s leverage is not the reported 6x but could be alarmingly between 10x-13x.
Grifols could face drastically higher financing costs if these claims are substantiated, potentially pushing the company into an&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36675593/spanish-healthcare-firm-grifols-reputational-damage-and-debt-woes-european-central-bank-probes-le" rel="noreferrer noopener">unsustainable financial position</a>.
Price Action:&nbsp;GRFS shares are down 9.70% at $5.73 on the last check Thursday.
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37713530/tiktok-bidding-war-mnuchin-kotick-emerge-as-potential-buyers">TikTok Bidding War? Mnuchin, Kotick Emerge As Potential Buyers</a>

Health Care

Grifols Gets Downgraded: Fitch, S&P Flag Cash Flow Concerns At Pharma Company

Grifols shares are trading lower after Fitch and S&P reportedly downgraded their credit ratings of the stock.

Grifols Expects To Address Our 2025 Maturities Efficiently In The First Half Of 2024, Considering The SRAAS Disposal Proceeds And Other Available Options; Executing These Commitments Will Help Grifols Achieve Leverage Levels That Should Serve As Basis For An Improvement On Credit Rating Agencies' Scorecards

Grifols Continues To Conduct Business As Usual And Remain Fully Committed To Implementing Its Plan To Reduce Leverage Through Accelerated EBITDA Improvement And Proceeds From $1.8B Shanghai Raas (SRAAS) 20% Sale; Such Disposal Execution Continues To Follow Already-Stated Timings And Is Expected To Close In The H1 Of 2024

<h3>Gainers</h3>
<ul>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock moved upwards by 23.65% to $11.92. The company's market cap stands at $211.8 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) stock moved upwards by 20.99% to $0.34. The market value of their outstanding shares is at $62.5 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) shares rose 14.38% to $1.59. The market value of their outstanding shares is at $55.2 million. </li>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) shares rose 13.57% to $8.2. The company's market cap stands at $251.0 million. </li>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) stock moved upwards by 13.34% to $6.54. The company's market cap stands at $511.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares fell 78.0% to $1.14 during Thursday's pre-market session. The company's market cap stands at $46.4 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock decreased by 15.65% to $0.1. The company's market cap stands at $4.0 million. </li>
<li>Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) stock decreased by 12.04% to $2.12. The market value of their outstanding shares is at $464.3 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) stock declined by 9.15% to $5.76. The market value of their outstanding shares is at $3.9 billion. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares decreased by 8.97% to $0.59. The company's market cap stands at $21.1 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock fell 8.39% to $0.45. The company's market cap stands at $4.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

BPTS

Kintara Therapeutics, Inc. - Common Stock

KTRA

NUVB

NVCT

SPRB

TELO

UNCY

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Deutsche Bank analyst Emmanuel Papadakis downgrades Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) from Hold to Sell.

Downgrades

Analyst Ratings

Deutsche Bank Downgrades Grifols to Sell

Shares of Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) fell sharply during Friday&rsquo;s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Marvell said fourth-quarter revenue increased 1% year-over-year to $1.427 billion, which beat the consensus estimate of $1.42 billion. The chip designer reported quarterly earnings of 46 cents per share, which was in line with analyst estimates.
Marvell sees first-quarter revenue of $1.15 billion, plus or minus 5%, versus estimates of $1.371 billion. The company sees first-quarter adjusted earnings of 23 cents per share, plus or minus 5 cents per share, versus estimates of 40 cents per share. The company authorized a $3 billion buyback.
Marvell Technology shares dipped 9.6% to $76.91 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
Ainos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) jumped 140% to $2.6899 after dipping 18% on Thursday.
Psyence Biomedical Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbm#NASDAQ">PBM</a>) shares climbed 139% to $3.0350. Psyence Biomedical recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study.
Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) shares jumped 138% to $1.57 after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia.
MIRA Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mira#NASDAQ">MIRA</a>) shares climbed 48.5% to $1.36. MIRA Pharmaceuticals, last month, announced a research collaboration with Pharmaseed to research and evaluate Ketamir for patients with major depressive disorder and post-traumatic stress disorder.
CERo Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cero#NASDAQ">CERO</a>) shares climbed 35.4% to $4.17 after surging over 20% on Thursday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients.
Willdan Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wldn#NASDAQ">WLDN</a>) gained 30.4% to $25.89 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years.
The Joint Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jynt#NASDAQ">JYNT</a>) gained 29% to $11.80 following fourth-quarter results.
Smith &amp; Wesson Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swbi#NASDAQ">SWBI</a>) jumped 25.8% to $16.91 after the company reported better-than-expected third-quarter financial results.
Research Frontiers Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/refr#NASDAQ">REFR</a>) climbed 25.6% to $1.42 following fourth-quarter results.
Gulf Island Fabrication, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gifi#NASDAQ">GIFI</a>) shares gained 24.1% to $6.43 after the company reported a year-over-year increase in fourth-quarter revenue results.
Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) gained 22.7% to $6.89 after the company announced it published its consolidated annual accounts for 2023.
DoubleDown Interactive Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddi#NASDAQ">DDI</a>) gained 21.6% to $14.25.
Dogness (International) Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dogz#NASDAQ">DOGZ</a>) gained 18.6% to $7.98.
Kidpik Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pik#NASDAQ">PIK</a>) gained 18.3% to $3.0177.
America&#39;s Car-Mart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crmt#NASDAQ">CRMT</a>) jumped 16.5% to $72.56 following third-quarter results.
Porch Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prch#NASDAQ">PRCH</a>) rose 16.1% to $3.6099 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance.
Samsara Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iot#NYSE">IOT</a>) gained 14.3% to $39.28 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance above estimates.
Viracta Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/virx#NASDAQ">VIRX</a>) shares gained 13.5% to $0.9200 following fourth-quarter results.
Aeva Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeva#NASDAQ">AEVA</a>) rose 12.6% to $1.34.
Adaptimmune Therapeutics plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adap#NASDAQ">ADAP</a>) gained 12.1% to $1.95. Adaptimmune Therapeutics recently reported better-than-expected quarterly EPS results.
HCI Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hci#NYSE">HCI</a>) gained 11.3% to $110.42 after the company reported better-than-expected fourth-quarter financial results.
NuScale Power Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smr#NYSE">SMR</a>) jumped 10.5% to $4.9289.
Redfin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdfn#NASDAQ">RDFN</a>) jumped 9.6% to $7.10.
reAlpha Tech Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aire#NASDAQ">AIRE</a>) rose 8.8% to $1.3599. reAlpha Tech, last month, appointed Michael Frenz as CFO and Mike Logozzo as President and COO.
Carnival Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccl#NYSE">CCL</a>) gained 5% to $16.44.
<h3>Losers</h3>
Amylyx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amlx#NASDAQ">AMLX</a>) shares fell 80.7% to $3.6596 after the company announced its PHOENIX phase 3 trial of AMX0035 for amyotrophic lateral sclerosis did not meet its primary endpoint and there was no statistical significance seen in secondary endpoints.
BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) fell 30.8% to $2.6006 after the company reported worse-than-expected fourth-quarter financial results.
Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) tumbled 28.6% to $0.0819.
Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 27.7% to $7.95.
Swvl Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) fell 26.3% to $5.45.
Immuron Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrn#NASDAQ">IMRN</a>) shares dipped 24.7% to $3.4250 after jumping 161% on Thursday.
AerSale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asle#NASDAQ">ASLE</a>) fell 24.4% to $7.11 after the company reported worse-than-expected fourth-quarter financial results.
CarParts.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prts#NASDAQ">PRTS</a>) fell 24.3% to $1.8999 following fourth-quarter results.
Mobix Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mobx#NASDAQ">MOBX</a>) fell 20.1% to $1.39.
Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) fell 19% to $0.8001 after surging 28% on Thursday. Nxu recently announced it successfully charged a Tesla Cybertruck.
Brera Holdings PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brea#NASDAQ">BREA</a>) shares fell 16.9% to $1.62. Brera Holdings shares jumped 91% on Thursday after the company announced that its Executive Chairman, Daniel McClory, acquired a majority stake in the company. 
Custom Truck One Source, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctos#NYSE">CTOS</a>) dipped 15.3% to $5.26 after the company reported mixed quarterly financial results.
Nexalin Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxl#NASDAQ">NXL</a>) fell 15.1% to $0.4627. Nexalin Technology recently announced results of a clinical study of its Gen-2 tACS device for the treatment of chronic insomnia.
Runway Growth Finance Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rway#NASDAQ">RWAY</a>) fell 13.5% to $11.68 following downbeat quarterly results.
Domo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/domo#NASDAQ">DOMO</a>) fell 12.7% to $9.92 after the company issued soft first-quarter and FY25 guidance.
MediaAlpha, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/max#NYSE">MAX</a>) declined 12.4% to $19.05 after the company announced a secondary offering of 3 million shares.
Genesco Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gco#NYSE">GCO</a>) fell 11.7% to $25.84 after the company&#39;s reported a fourth-quarter EPS miss and issued weak FY25 guidance.
Delek Logistics Partners, LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dkl#NYSE">DKL</a>) fell 11.3% to $39.51 after the company priced a public offering of 3,116,884 common units at $38.50 per unit.
Grom Social Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grom#NASDAQ">GROM</a>) fell 11% to $1.13 after jumping 65% on Thursday. The company announced that it entered into a non-binding letter of intent to acquire Arctic7.
Traeger, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cook#NYSE">COOK</a>) fell 10.5% to $2.11 after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued FY24 revenue guidance below estimates.
Aquestive Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aqst#NASDAQ">AQST</a>) dipped 10% to $5.11 following fourth-quarter results.
Petr&oacute;leo Brasileiro S.A. - Petrobras (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbr#NYSE">PBR</a>) shares fell 9.6% to $15.10 as the company reported a 6.3% year-over-year decline in its fourth-quarter net recurring profit.
Costco Wholesale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cost#NASDAQ">COST</a>) fell 7.5% to $727.08 following mixed second-quarter results.
MongoDB, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>) declined 6.4% to $385.82 after the company issued weak FY25 guidance.
Icahn Enterprises L.P. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iep#NASDAQ">IEP</a>) fell 4.7% to $17.85.
RadNet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>) dipped 4.1% to $46.54. RadNet priced its public offering of 4.55 million common stock at $44 per share.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37553898/cramer-says-sprout-social-is-in-a-hot-spot-but-this-energy-stock-is-too-down-and-out"> Cramer Says Sprout Social Is In A &#39;Hot Spot,&#39; But This Energy Stock Is &#39;Too Down And Out&#39; </a>

ADAP

AEVA

AIMD

AIRE

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AQST

ASLE

BBAI

BREA

CERO

COOK

COST

CRML

CRMT

CTOS

DOGZ

DOMO

GIFI

GROM

IMRN

JYNT

MIRA

MOBX

MRVL

PRCH

PRTS

RDFN

RDNT

REFR

RWAY

SWBI

SWVL

VIRX

WLDN

Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 80 points on Friday.
The Dow traded up 0.21% to 38,874.05 while the NASDAQ fell 0.42% to 16,204.26. The S&amp;P 500 also fell, dropping, 0.13% to 5,150.72.
Check This Out: <a href="https://www.benzinga.com/news/24/03/37556716/wall-streets-most-accurate-analysts-views-on-3-risk-off-stocks-with-over-5-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Risk Off Stocks With Over 5% Dividend Yields </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Real estate shares jumped by 1.1% on Friday.
In trading on Friday, consumer staples shares fell by 0.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Nonfarm payrolls beat economist estimates, coming at 275,000 in February compared to the expected 200,000. The unemployment rate rose from 3.7% to 3.9%, surprising estimates of 3.7%.
Average hourly wages grew at a 0.1% monthly pace in February, easing from the downwardly revised 0.5% growth in January, and below the expected 0.3%.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Willdan Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wldn#NASDAQ">WLDN</a>) shares shot up 27% to $25.16 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years.
Shares of Gulf Island Fabrication, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gifi#NASDAQ">GIFI</a>) got a boost, surging 23% to $6.35 after the company reported a year-over-year increase in fourth-quarter revenue results.
Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) shares were also up, gaining 20% to $6.72 after the company announced it published its consolidated annual accounts for 2023.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Amylyx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amlx#NASDAQ">AMLX</a>) shares dropped 82% to $3.51 after the company announced its PHOENIX phase 3 trial of AMX0035 for amyotrophic lateral sclerosis did not meet its primary endpoint and there was no statistical significance seen in secondary endpoints.
Shares of Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) were down 34% to $0.0760.
BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) was down, falling 31% to $2.58 after the company reported worse-than-expected fourth-quarter financial results.
Also Check This Out:<a href="https://www.benzinga.com/news/24/03/37557834/cisco-robinhood-and-2-other-stocks-insiders-are-selling"> Cisco, Robinhood And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 1.2% to $77.99 while gold traded up 1.6% at $2,198.80.
Silver traded up 0.4% to $24.68 on Friday while copper fell 0.7% to $3.90.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 gained 0.02%, London&rsquo;s FTSE 100 fell 0.43% while Spain&rsquo;s IBEX 35 Index rose 0.13% The German DAX fell 0.16% French CAC 40 rose 0.15% while Italy&rsquo;s FTSE MIB Index fell 0.04%.
The eurozone economy stagnated during the fourth quarter compared to a 0.1% decline in the prior three-month period. French trade deficit increased to &euro;7.4 billion in January from &euro;6.4 billion in the prior month. Spanish industrial output declined by 0.6% year-over-year in January. Producer prices in Germany declined by 4.4% year-over-year in January, while industrial output increased by 1.0% month-over-month for January.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed higher on Friday, with Japan&rsquo;s Nikkei 225 gaining 0.23%, Hong Kong&rsquo;s Hang Seng Index gaining 0.76% and China&rsquo;s Shanghai Composite Index gaining 0.61%.
The gauge for Japan&rsquo;s service <a href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/">sector</a> climbed to 51.3 in February versus prior month&rsquo;s reading of 50.2. The index of leading economic indicators in Japan fell to 109.9 in January versus a revised reading of 110.5 in December, while index of coincident economic indicators fell to 110.2 in January versus a revised 116.0 in the previous month. Household spending in Japan dipped by 6.3% year-over-year in January.
&nbsp;
<h3>Economics</h3>
&nbsp;
Nonfarm payrolls beat economist estimates, coming at 275,000 in February compared to the expected 200,000.
The unemployment rate rose from 3.7% to 3.9%, surprising estimates of 3.7%.
Average hourly wages grew at a 0.1% monthly pace in February, easing from the downwardly revised 0.5% growth in January, and below the expected 0.3%.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37556718/top-3-industrials-that-are-preparing-to-pump-in-q1"> Top 3 Industrials That Are Preparing To Pump In Q1</a>

Earnings

Eurozone

Commodities

Global

Crude Oil Falls Over 1%; Willdan Group Shares Spike Higher

<h3>Gainers</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 137.8% to $3.02 during Friday's regular session. The market value of their outstanding shares is at $40.4 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock moved upwards by 91.96% to $2.15. The company's market cap stands at $10.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares increased by 34.75% to $1.28. The company's market cap stands at $18.9 million. </li>
<li>Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) stock rose 29.1% to $11.8. The market value of their outstanding shares is at $174.1 million. The company's, Q4 earnings came out yesterday. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock rose 25.11% to $8.32. The market value of their outstanding shares is at $89.3 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) stock increased by 19.69% to $6.71. The market value of their outstanding shares is at $4.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) shares declined by 81.5% to $3.52 during Friday's regular session. The market value of their outstanding shares is at $238.2 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock fell 25.94% to $3.37. The market value of their outstanding shares is at $19.1 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares fell 22.94% to $7.09. The company's market cap stands at $1.1 billion. </li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) shares fell 16.55% to $12.51. The market value of their outstanding shares is at $42.7 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock declined by 14.27% to $4.84. The market value of their outstanding shares is at $64.4 million. </li>
<li>Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) stock declined by 13.72% to $3.46. The market value of their outstanding shares is at $79.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASI

EFTR

LTRN

TSBX

ZJYL

12 Health Care Stocks Moving In Friday's Intraday Session

Grifols SA - ADR ADR Class B (GRFS) is lower by Monday morning, with the stock losing -1.47% in pre-market trading to 6.04. GRFS's short-term technical score of 10 indicates that the stock has traded less bullishly over the last month than 90% of stocks on the market. In the Drug Manufacturers - General industry, which ran

Premarket Mover: Grifols SA - ADR ADR Class B (GRFS) Down 1.47%

Grifols SA - ADR ADR Class B (GRFS) is up 2.54% today. GRFS has an Overall Score of 36. Find out what this means to you and get the rest of the rankings on GRFS!See Full GRFS ReportGRFS stock closed at $6.29 and is up $0.16 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as

Premarket Mover: Grifols SA - ADR ADR Class B (GRFS) Up 2.54%

Spanish regulators find no major errors in Grifols accounting: report

Spanish regulators find no major errors in Grifols' accounting: report

Grifols SA - ADR ADR Class B (GRFS) is lower by Friday morning, with the stock falling -9.73% in pre-market trading to 6.12. GRFS's short-term technical score of 53 indicates that the stock has traded more bullishly over the last month than 53% of stocks on the market. In the Drug Manufacturers - General industry, which ra

Grifols SA - ADR ADR Class B (GRFS) Down 9.73% in Premarket Trading

STEM, SOUN and GRFS among pre-market losers

European losers of higher financing costs - JPMorgan

ATUS, ATHE and GRFS among pre-market losers

Grifols reportedly looking to appoint independent directors

Grifols SA (GRFS) has disclosed a new risk, in the Debt & Financing category. Grifols SA engages in various transactions with related parties, whic...

Grifols SA's Related Party Transactions: Navigating Conflicts of Interest and Investor Concerns